Affordable Access

deepdyve-link
Publisher Website

Application of a Refined Developability Classification System.

Authors
  • Rosenberger, Julian1
  • Butler, James2
  • Muenster, Uwe3
  • Dressman, Jennifer4
  • 1 Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany. , (Germany)
  • 2 Product Development and Supply, GlaxoSmithKline R&D, Ware, UK.
  • 3 Chemical and Pharmaceutical Development, Research & Development, Pharmaceuticals, Bayer AG, Wuppertal, Germany. , (Germany)
  • 4 Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany. Electronic address: [email protected] , (Germany)
Type
Published Article
Journal
Journal of Pharmaceutical Sciences
Publisher
Elsevier
Publication Date
Mar 01, 2019
Volume
108
Issue
3
Pages
1090–1100
Identifiers
DOI: 10.1016/j.xphs.2018.10.044
PMID: 30389565
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

In 2010, the Developability Classification System was proposed as an extension of the Biopharmaceutics Classification System to align the classification system with the need for early evaluation of drug candidates according to their developability as oral formulations. Recent work on the Developability Classification System has resulted in the refined developability classification system (rDCS), consisting of standard investigations to estimate drug candidate solubility and permeability and offering customized investigations that are triggered when there is a potential for supersaturation/precipitation (e.g., salts of acids, weak bases) or to investigate permeation versus dissolution-limited absorption. In the present study, the rDCS concept was successfully applied to 6 marketed compounds (aciclovir, albendazole, danazol, dantrolene, dipyridamole, and piroxicam), for which there is a rich database of information. Furthermore, the rDCS was applied to 20 pipeline compounds from past and current research projects at Bayer AG. The rDCS was able to predict the results in humans correctly in 80% of cases. Overall, the results suggest that the rDCS is a highly useful tool for estimating the in vivo behavior of new drug candidates. Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times